Qiagen Buys Cellestis For QuantiFeron “Pre-Molecular” Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Qiagen plans to incorporate Cellestis’ QuantiFeron “pre-molecular” diagnostics technology into its own automated and mobile testing platforms after acquiring the firm for $355 million in a deal announced April 3.
You may also be interested in...
News In Brief
Valeant gains Sculptra for wrinkles
News In Brief
Valeant gains Sculptra for wrinkles
News In Brief
Qiagen proposes Ipsogen purchase